Stay updated with breaking news from Corbus Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares are surging more than 256 percent on Friday morning trade after the company announced that the data from the first-in-human clinical study of CRB-701 demonstrated encouraging safety and efficacy in patients with Nectin-4 positive tumors in the first human study.
The prevalence of obesity has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Obesity and the growing research and
/PRNewswire/ -- DelveInsight's 'Obesity Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline obesity...
/PRNewswire/ -- The "Trikafta Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. Global Trikafta market...
/PRNewswire/ -- The "Trikafta Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. Global Trikafta market...